Significant shareholders:
| Shareholder/Beneficial Owner | Shares | % ISC |
|---|---|---|
| Invesco | 142,478,483 | 17.78 |
| T Rowe Price Global Investments | 96,897,779 | 12.09 |
| Canaccord Genuity Wealth Management | 58,176,938 | 7.26 |
| Hargreaves Lansdown, stockbrokers | 54,721,229 | 6.83 |
| Dr Andrew W Nelson* | 36,140,417 | 4.54 |
| Interactive Investor | 33,019,510 | 4.12 |
| AXA Framlington Investment Managers | 26,335,606 | 3.29 |
| Barclays Smart Investor | 24,679,403 | 3.08 |
as at 30 April 2021
Quoted: AIM (London Stock Exchange)
Other Exchanges / Trading Platforms: The Company is not listed on any other exchanges or trading platforms.
Number of securities in issue: 800,788,829 Ordinary shares
Shares not in public hands: Insofar as the Company is aware, the percentage of securities that is not in public hands is 33.8%, these being held by directors, their families and significant shareholders.
Own shares held in treasury: There are currently no IQE plc shares held in treasury.
Details on any restrictions on the transfer of securities: There are no restrictions on the transfer of securities.
Applicable code(s): The Company is subject to the UK City Code on Takeovers and Mergers. The Code is administered by The Panel and Takeovers in Mergers.
* Per the Company’s RNS announcement of 11 May 2020, 12,121,711 Ordinary Shares of Dr Nelson’s total beneficial interest are subject to a Sale and Repurchase Agreement with Equities First Holdings